DK3019153T3 - Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation - Google Patents
Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation Download PDFInfo
- Publication number
- DK3019153T3 DK3019153T3 DK14747855.6T DK14747855T DK3019153T3 DK 3019153 T3 DK3019153 T3 DK 3019153T3 DK 14747855 T DK14747855 T DK 14747855T DK 3019153 T3 DK3019153 T3 DK 3019153T3
- Authority
- DK
- Denmark
- Prior art keywords
- particles
- dry powder
- powder formulation
- fraction
- formulation according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (11)
1. Tørpulverformulering til anvendelse i en tørpulverinhalator (DPI) til afgivelse ved inhalation af en kombination af mikroniserede partikler af glycopyrronium-bromid, beclometasondipropionat og formoterolfumaratdihydrat som aktive bestanddele i en kombineret terapeutisk virksom dosis på 100 til 500 pg, hvor formuleringen omfatter: a) en fraktion af fine partikler bestående af en blanding på 90 til 99,5 vægtprocent af mikroniserede partikler af et fysiologisk acceptabelt hjælpestof og 0,5 til 10 vægtprocent magnesiumstearat, hvor mindst 90 % af alle partiklerne har en volumendiameter på mindre end 12 mikron, den gennemsnitlige volumendiameter af partiklerne er på 3 til 7 mikron, og ikke mere end 10 % af partiklerne har en diameter, der er lavere end 1,5 mikron; b) en fraktion af grove partikler bestående af et fysiologisk acceptabelt hjælpestof, der har en gennemsnitlig massediameter, der er lig med eller højere end 175 mikron, hvor forholdet mellem de fine partikler a) og de grove partikler b) er mellem 1:99 og 30:70 vægtprocent; hvor mindst 90 % af alle mikroniserede partikler af de aktive bestanddele har en volumendiameter, der er lavere end 6,0 mikron, deres gennemsnitlige volumendiameter er mellem 1,2 og 2,5 mikron og bredden af deres partikelstørrelsesfordeling, udtrykt som et spænd, ligger mellem 1,2 og 3,0; hvor formuleringen opnås ved en fremgangsmåde omfattende de følgende trin: i) at fremstille fraktionen af fine partikler a) ved co-blanding i en højenergiindretning i en periode på mindre end 20 minutter, ii) at blande fraktionen af fine partikler a), fraktionen af grove partikler b) og alle de mikroniserede aktive bestanddele.
2. Tørpulverformulering ifølge krav 1, hvor de fine partikler a) co-blandes i et tidsrum på mellem 2 og 15 minutter.
3. Tørpulverformulering ifølge krav 1 eller 2, hvor mindst 90 % af de mikroniserede partikler af de aktive bestanddele har en volumendiameter, der er lig med eller lavere end 5,0 mikron.
4. Tørpulverformulering ifølge krav 3, hvor den gennemsnitlige volumendiameter af partiklerne ligger mellem 1,3 og 2,2 mikron.
5. Tørpulverformulering ifølge et af kravene 1 til 4, hvor magnesiumstearat dækker overfladen af de overskydende partikler a) på en sådan måde, at overfladebelægningens omfang er mindst 50%.
6. Tørpulverformulering ifølge krav 5, hvor højenergi-indretningen er en me-chano-fusionsindretning.
7. Tørpulverformulering ifølge et af de foregående krav, hvor forholdet mellem de fine partikler a) og de grove partikler b) ligger mellem 5:95 og 15:85 vægtprocent.
8. Tørpulverformulering ifølge et af de foregående krav, hvor diameteren af de grove partikler b) ligger mellem 210 og 355 mikron.
9. Tørpulverinhalatorindretning omfattende en tørpulverformulering ifølge et af kravene 1 til 8.
10. Tørpulverformulering ifølge et af kravene 1 til 8 til anvendelse ved forebyggelse og/eller behandling af en inflammatorisk eller obstruktiv luftvejssygdom.
11. Tørpulverformulering ifølge krav 10, hvor den inflammatoriske og/eller ob-struktive luftvejssygdom er kronisk obstruktiv lungesygdom (COPD).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176114 | 2013-07-11 | ||
| EP13194763 | 2013-11-28 | ||
| PCT/EP2014/064824 WO2015004243A1 (en) | 2013-07-11 | 2014-07-10 | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3019153T3 true DK3019153T3 (da) | 2018-11-19 |
Family
ID=51292914
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14747855.6T DK3019153T3 (da) | 2013-07-11 | 2014-07-10 | Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation |
| DK19182016.6T DK3569222T3 (da) | 2013-07-11 | 2014-07-10 | Tørpulverformulering omfattende en anticholinergikum, en corticosteroid og en beta-andrenergikum til indgivelse ved inhalering |
| DK18178893.6T DK3409270T3 (da) | 2013-07-11 | 2014-07-10 | Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19182016.6T DK3569222T3 (da) | 2013-07-11 | 2014-07-10 | Tørpulverformulering omfattende en anticholinergikum, en corticosteroid og en beta-andrenergikum til indgivelse ved inhalering |
| DK18178893.6T DK3409270T3 (da) | 2013-07-11 | 2014-07-10 | Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US9402825B2 (da) |
| EP (3) | EP3569222B1 (da) |
| JP (1) | JP6426167B2 (da) |
| KR (2) | KR20160029797A (da) |
| CN (1) | CN105338960B (da) |
| AR (1) | AR129501A2 (da) |
| AU (1) | AU2014289185B2 (da) |
| BR (1) | BR112015030914B1 (da) |
| CA (1) | CA2917752C (da) |
| CL (1) | CL2016000028A1 (da) |
| CY (2) | CY1120806T1 (da) |
| DK (3) | DK3019153T3 (da) |
| EA (1) | EA029125B1 (da) |
| ES (2) | ES2699986T3 (da) |
| FI (1) | FI3569222T3 (da) |
| GE (1) | GEP20186853B (da) |
| HK (1) | HK1218712A1 (da) |
| HR (2) | HRP20182008T1 (da) |
| HU (2) | HUE053957T2 (da) |
| IL (1) | IL243507A0 (da) |
| LT (3) | LT3569222T (da) |
| MX (1) | MX2016000290A (da) |
| MY (1) | MY176176A (da) |
| NZ (1) | NZ715797A (da) |
| PE (2) | PE20212110A1 (da) |
| PH (1) | PH12016500043A1 (da) |
| PL (2) | PL3019153T3 (da) |
| PT (1) | PT3019153T (da) |
| RS (2) | RS61652B1 (da) |
| SA (1) | SA516370373B1 (da) |
| SG (1) | SG11201600110RA (da) |
| SI (2) | SI3409270T1 (da) |
| TN (1) | TN2016000007A1 (da) |
| TW (1) | TWI642450B (da) |
| UA (1) | UA116907C2 (da) |
| WO (1) | WO2015004243A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160853A1 (es) * | 2009-12-23 | 2016-09-14 | Chiesi Farm Spa | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) |
| RS63706B1 (sr) * | 2012-01-25 | 2022-11-30 | Chiesi Farm Spa | Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom |
| PL3019153T3 (pl) * | 2013-07-11 | 2019-02-28 | Chiesi Farmaceutici S.P.A. | Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny do podawania wziewnego |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| US9554992B2 (en) | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
| TR201407010A2 (tr) | 2014-06-16 | 2015-12-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Vilanterol formülasyonları. |
| JP6600961B2 (ja) * | 2015-03-30 | 2019-11-06 | ブラザー工業株式会社 | 表示制御装置、表示制御方法及び記憶媒体 |
| CA2983427C (en) * | 2015-05-01 | 2024-04-23 | Board Of Regents, The University Of Texas System | Multidrug brittle matrix compositions |
| HUE056402T2 (hu) | 2015-11-16 | 2022-02-28 | Chiesi Farm Spa | Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására |
| DK3620176T3 (da) | 2015-11-16 | 2021-09-20 | Chiesi Farm Spa | Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum |
| DE202017007661U1 (de) * | 2016-11-10 | 2024-02-21 | Medisca Pharmaceutique Inc. | System zur pharmazeutischen Zubereitung |
| BR112019023386A2 (pt) * | 2017-05-11 | 2020-06-16 | Chiesi Farmaceutici S.P.A. | Processo para preparar uma formulação em pó para inalação para uso em um inalador de pó seco |
| US10786450B2 (en) * | 2017-05-11 | 2020-09-29 | Chiesi Farmaceutici S.P.A. | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
| CN109200034A (zh) * | 2017-06-30 | 2019-01-15 | 正大天晴药业集团股份有限公司 | 一种可吸入干粉形式的组合物及其制备方法 |
| WO2019060595A1 (en) | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| EP4034079A1 (en) | 2019-09-24 | 2022-08-03 | Chiesi Farmaceutici S.p.A. | Novel carrier particles for dry powder formulations for inhalation |
| US12029709B2 (en) * | 2022-08-11 | 2024-07-09 | De Motu Cordis Pty Ltd | Inhalable epinephrine formulation |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2347856C (en) * | 1998-11-13 | 2009-02-17 | Jago Research Ag | Dry powder for inhalation |
| US20070212422A1 (en) | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| AU6926101A (en) * | 2000-06-27 | 2002-01-08 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
| EP1920763B2 (en) * | 2000-11-30 | 2022-06-15 | Vectura Limited | Pharmaceutical compositions for inhalation |
| PT1658872E (pt) | 2002-07-31 | 2011-05-12 | Chiesi Farma Spa | Inalador de p? |
| JO3102B1 (ar) * | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP1944018A1 (en) * | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
| BR112012015334A2 (pt) | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| PE20160853A1 (es) * | 2009-12-23 | 2016-09-14 | Chiesi Farm Spa | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) |
| TR201000681A2 (tr) | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | İnhalasyon yoluyla alınan kuru toz formülasyonları. |
| WO2011120779A1 (en) * | 2010-04-01 | 2011-10-06 | Chiesi Farmaceutici S.P.A. | Process for preparing carrier particles for dry powders for inhalation |
| EP2560611B1 (en) * | 2010-04-21 | 2018-01-03 | Chiesi Farmaceutici S.p.A. | "process for providing particles with reduced electrostatic charges" |
| WO2011160920A1 (en) * | 2010-06-22 | 2011-12-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulation comprising an antimuscarinic drug |
| RS63706B1 (sr) * | 2012-01-25 | 2022-11-30 | Chiesi Farm Spa | Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom |
| US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| PL3019153T3 (pl) * | 2013-07-11 | 2019-02-28 | Chiesi Farmaceutici S.P.A. | Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny do podawania wziewnego |
-
2014
- 2014-07-10 PL PL14747855T patent/PL3019153T3/pl unknown
- 2014-07-10 GE GEAP201414032A patent/GEP20186853B/en unknown
- 2014-07-10 US US14/327,920 patent/US9402825B2/en active Active
- 2014-07-10 JP JP2016524826A patent/JP6426167B2/ja active Active
- 2014-07-10 KR KR1020167000719A patent/KR20160029797A/ko not_active IP Right Cessation
- 2014-07-10 EP EP19182016.6A patent/EP3569222B1/en active Active
- 2014-07-10 BR BR112015030914-3A patent/BR112015030914B1/pt active IP Right Grant
- 2014-07-10 LT LTEP19182016.6T patent/LT3569222T/lt unknown
- 2014-07-10 EA EA201690006A patent/EA029125B1/ru unknown
- 2014-07-10 ES ES14747855T patent/ES2699986T3/es active Active
- 2014-07-10 HU HUE18178893A patent/HUE053957T2/hu unknown
- 2014-07-10 TW TW103123763A patent/TWI642450B/zh active
- 2014-07-10 LT LTEP18178893.6T patent/LT3409270T/lt unknown
- 2014-07-10 PE PE2021000280A patent/PE20212110A1/es unknown
- 2014-07-10 EP EP14747855.6A patent/EP3019153B1/en active Active
- 2014-07-10 SI SI201431806T patent/SI3409270T1/sl unknown
- 2014-07-10 SG SG11201600110RA patent/SG11201600110RA/en unknown
- 2014-07-10 TN TN2016000007A patent/TN2016000007A1/en unknown
- 2014-07-10 MX MX2016000290A patent/MX2016000290A/es active IP Right Grant
- 2014-07-10 AU AU2014289185A patent/AU2014289185B2/en active Active
- 2014-07-10 RS RS20210320A patent/RS61652B1/sr unknown
- 2014-07-10 KR KR1020217018070A patent/KR102275904B1/ko active IP Right Grant
- 2014-07-10 EP EP18178893.6A patent/EP3409270B1/en active Active
- 2014-07-10 PE PE2016000025A patent/PE20160372A1/es unknown
- 2014-07-10 UA UAA201600204A patent/UA116907C2/uk unknown
- 2014-07-10 NZ NZ715797A patent/NZ715797A/en unknown
- 2014-07-10 DK DK14747855.6T patent/DK3019153T3/da active
- 2014-07-10 RS RS20181254A patent/RS57799B1/sr unknown
- 2014-07-10 FI FIEP19182016.6T patent/FI3569222T3/fi active
- 2014-07-10 DK DK19182016.6T patent/DK3569222T3/da active
- 2014-07-10 MY MYPI2016000023A patent/MY176176A/en unknown
- 2014-07-10 SI SI201430976T patent/SI3019153T1/sl unknown
- 2014-07-10 CA CA2917752A patent/CA2917752C/en active Active
- 2014-07-10 ES ES18178893T patent/ES2867552T3/es active Active
- 2014-07-10 HU HUE14747855A patent/HUE039827T2/hu unknown
- 2014-07-10 DK DK18178893.6T patent/DK3409270T3/da active
- 2014-07-10 LT LTEP14747855.6T patent/LT3019153T/lt unknown
- 2014-07-10 PT PT14747855T patent/PT3019153T/pt unknown
- 2014-07-10 WO PCT/EP2014/064824 patent/WO2015004243A1/en active Application Filing
- 2014-07-10 CN CN201480037266.1A patent/CN105338960B/zh active Active
- 2014-07-10 PL PL18178893T patent/PL3409270T3/pl unknown
-
2016
- 2016-01-07 PH PH12016500043A patent/PH12016500043A1/en unknown
- 2016-01-07 SA SA516370373A patent/SA516370373B1/ar unknown
- 2016-01-07 IL IL243507A patent/IL243507A0/en active IP Right Grant
- 2016-01-08 CL CL2016000028A patent/CL2016000028A1/es unknown
- 2016-05-20 US US15/160,593 patent/US9808422B2/en active Active
- 2016-06-10 HK HK16106687.7A patent/HK1218712A1/zh unknown
-
2018
- 2018-11-01 CY CY181101132T patent/CY1120806T1/el unknown
- 2018-11-29 HR HRP20182008TT patent/HRP20182008T1/hr unknown
-
2021
- 2021-03-12 CY CY20211100219T patent/CY1123937T1/el unknown
- 2021-05-06 HR HRP20210704TT patent/HRP20210704T1/hr unknown
-
2023
- 2023-06-01 AR ARP230101391A patent/AR129501A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3019153T3 (da) | Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation | |
| US10772896B2 (en) | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| US10959944B2 (en) | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |